Friday’s trading has closed, but UTHR is being traded in the after-hours session.
After-Hours quote »| 66.35 Data as of 4:00pm ET |  -1.26 / -1.86%Today’s Change | 42.12 Today|||52-Week Range 69.65 | +24.20% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $3.4B |
Company Description
United Therapeutics Corp. operates as a biotechnology company, which focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company operates in two business segments: Pharmaceuticals and Telemedicine. Its primary product Remodulin is used for the treatment of pulmonary arterial hypertension and the company also develops glycol-biological antiviral agents for the treatment of infectious diseases, such as Hepatitis C. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Employees
Shareholders
| Other institutional | 55.61% |
| Mutual fund holders | 52.21% |
| Individual stakeholders | 12.42% |
Top Executives
| Martine A. Rothblatt, PhD, MBA | Chairman & Chief Executive Officer |
| Roger Jeffs, PhD | President, Chief Operating Officer & Director |
| John Maxim Ferrari | Chief Financial Officer & Treasurer |
| Shola Oyewole | Chief Information Officer |
| Paul A. Mahon | Secretary, Executive VP & General Counsel |
.
